DLA Piper has advised the shareholders of Pangaea Laboratories, a global beauty business and owner of the fast-growing Medik8 skincare brand, in connection with the investment from private equity firm Inflexion.

Medik8 is a premium, science-based, skincare brand. With a strong heritage in the international professional channel and a growing online presence, Medik8 is committed to ethical manufacturing and sustainability.

The DLA Piper team was led by Birmingham-based Corporate partner and Global Co-Chair of the Consumer Goods, Food and Retail sector, Noel Haywood, working alongside senior associate Simon Wright and supported by associate Kirsty Underhill, who acted on behalf of the shareholders of Pangaea Laboratories.

Representing the shareholders on their equity roll-over into the purchasing vehicle was DLA Piper’s European Head of Private Equity Tim Wright, supported by senior associate Camille Lagache.

Commenting on the transaction, Noel Haywood said: “This deal underlines both our firm’s market-leading M&A practice and its consumer products expertise and demonstrates the continuing opportunities for attractive assets in buoyant market segments including purpose-led and organic personal care products which have convincingly weathered the effects of the COVID-19 pandemic. It was also a particularly pleasing milestone for DLA Piper’s Management Advisory team which has now acted for 50 management teams in just over five years with a combined enterprise value of over EUR50 billion.”